Key result
Primary prevention statins in adults 80+ linked to lower mortality and coronary morbidity.
Why the study?
Does persistent statin therapy reduce mortality and coronary events in adults aged 80 and older without prior cardiovascular disease?
Cohort (n=15,745)
Does persistent statin therapy reduce mortality and coronary events in adults aged 80 and older without prior cardiovascular disease?
In adults aged 80 and older, persistent statin therapy for primary prevention is associated with significant reductions in all-cause mortality and new coronary events without increasing the risk of adverse events.
Answers are grounded in this paper and cite their sources.
May support statin use for primary prevention in adults ≥80; extends evidence to this understudied population.
BACKGROUND: Evidence supporting the use of statins for primary prevention of cardiovascular disease (CVD) in individuals aged ≥ 80 years remains limited. This study aimed to evaluate the long-term clinical benefits and safety of statins for primary prevention in patients aged 80 years and older. METHODS: We conducted a population-based retrospective cohort study using electronic medical records and pharmacy dispensing data from Clalit Health Services in Israel, covering the period from January 2015 to December 2020. Patients aged ≥ 80 years without prior CVD who were persistent statin users were compared with similar patients not receiving statins. Exclusions included prior CVD, dialysis, or death within 1 year of follow-up. Outcomes included all-cause mortality, new coronary events, myopathy, dementia, and diabetes mellitus. Cox proportional hazards models, adjusted for potential confounders, were used to assess the association between statin use and clinical outcomes. RESULTS: Among 15,745 patients (mean age 84.5 years; 66% female), 8413 were statin users. Over a 4-year mean follow-up, statin use was associated with a 31% reduction in mortality (HR 0.69; 95% CI: 0.34-0.74; p < 0.001) and a 20% reduction in new coronary events (HR 0.80; 95% CI: 0.68-0.94; p = 0.008). No significant differences were observed in the incidence of myopathy, diabetes, or dementia. Benefits were not observed in patients who discontinued statins before age 80. CONCLUSIONS: In patients aged ≥ 80 years, statin therapy for primary prevention was associated with reduced all-cause mortality and coronary morbidity, without increased risk of adverse events. Early discontinuation diminished these benefits.
No takes yet. Share an insight, caveat, or question.
Lavon et al. (2026) conducted a cohort in Primary prevention of cardiovascular disease (n=15,745). Statin therapy vs. Similar patients not receiving statins was evaluated on All-cause mortality (HR 0.69, 95% CI 0.34-0.74, p=< 0.001). In adults aged ≥ 80 years without prior cardiovascular disease, statin use was associated with a 31% reduction in all-cause mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: